Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib versus capecitabine in previously treated advanced breast cancer
2006-001267-33Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Aug 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Sunitinib malate with Capecitabine (2 arms). Primary endpoint: Progression-free survival. Started Aug 2006; status: terminated.
02
Drugs
sunitinibcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-001267-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001267-33.